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SUMMARY
The ex vivo production of platelets depleted of human leukocyte antigen class I (HLA-I) could serve as a universal measure to overcome
platelet transfusion refractoriness caused by HLA-I incompatibility. Here, we developed human induced pluripotent cell-derived HLA-I-
deficient platelets (HLA-KO iPLATs) in a clinically applicable imMKCL system by genetic manipulation and assessed their immunogenic
properties including natural killer (NK) cells, which reject HLA-I downregulated cells. HLA-KO iPLATs were deficient for all HLA-I but did
not elicit a cytotoxic response by NK cells in vitro and showed circulation equal to wild-type iPLATs upon transfusion in our newly estab-
lished Hu-NK-MSTRG mice reconstituted with human NK cells. Additionally, HLA-KO iPLATs successfully circulated in an alloimmune
platelet transfusion refractorinessmodel of Hu-NK-MISTRGmice.Mechanistically, the lack of NK cell-activating ligands on plateletsmay
be responsible for evading the NK cell response. This study revealed the unique non-immunogenic property of platelets and provides a
proof of concept for the clinical application of HLA-KO iPLATs.
INTRODUCTION
Platelet transfusion is an essential treatment for patients
with thrombocytopenia (Szczepiorkowski and Dunbar,
2013; Estcourt et al., 2017). The standard blood source for
transfusion has been blood donors for many decades, and
guidelines have been set to optimize transfusion condi-
tions. However, this donation system requires large efforts
to keep supply-demand balance due to the short shelf life of
the platelet products (i.e., 4 days in Japan and 5 days in the
United States), the anticipated absolute shortage in the
near future in countries with aging societies, and the risk
of blood-borne infection. Moreover, alloimmune platelet
transfusion refractoriness (allo-PTR) is observed in approx-
imately 5%–15% of patients who receive platelet transfu-
sion, with the most dominant cause being the production
of alloantibodies against human leukocyte antigen class I
(HLA-I), which includes A, B, and C antigens (Pavenski
et al., 2013; Saito et al., 2002; Stanworth et al., 2015). In
such HLA-I-mediated allo-PTR, transfused platelets are
immediately rejected, except for HLA-I-compatible plate-
lets. However, the need to select compatible donors limits
the supply, with the most difficult cases being rare HLA-I
types.
Human induced pluripotent stem cells (iPSCs) have been
extensively studied as an ex vivo source for producing hu-
man cells and tissues (Karagiannis and Eto, 2016), and
iPSC-derived platelets have the potential to resolve the
aforementioned issues in current transfusion systems (Su-
gimoto and Eto, 2017). They can be produced without
donor dependency and with good manufacturing practice
from pathogen-free assured master cells devoid of blood-
borne infections. As an expandable master cell source for
platelets, we previously established immortalizedmegakar-
yocyte progenitor cell lines (imMKCLs) fromhuman iPSCs,
whereby the selectively qualified iPSC clone-derived
imMKCLs can be prepared beforehand (Nakamura et al.,
2014). To create imMKCLs, in the megakaryocyte (MK)-
lineage differentiation from iPSCs, three doxycycline
(DOX)-inducible transgenes, c-MYC, BCL-XL, and BMI1,
are introduced. In the presence of DOX, imMKCLs prolifer-
ate, whereas depletion of DOX from the culture medium
leads to the maturation of imMKCLs to produce platelets
(whichwe call iPLATs).We recently succeeded at producing
the clinically required order of competent iPLATs by
maturing imMKCLs under turbulent flow conditions con-
sisting of optimal rages of turbulent energy and shear stress
(Ito et al., 2018). From the perspective of alloimmune
compatibility, the ideal platelet product is autologous.
Because iPSCs can be autologous, so too can iPLATs, but
autologous products have high cost and are of variable
quality. Therefore, the production of HLA-I homologous
platelets as an off-the-shelf product from a clinically appli-
cable iPSC library is under consideration (Gourraud et al.,
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2012; Turner et al., 2013). However, due to high variability
of theHLA-I gene, there is still a need to prepare awide line-
up of HLA-I types.
Platelets depleted of HLA-I can potentially be used as a
universally effective transfusion measure for HLA-I-medi-
ated allo-PTR. For depletion of HLA-I, genetic manipula-
tion of the HLA-I complex molecule b2-microglobulin
(B2M) has been shown to be effective (Gras et al., 2013;
Riolobos et al., 2013; Feng et al., 2014). The knockout pro-
cedure can completely deplete HLA-I expression for all A,
B, C, and E antigens (‘‘HLA-KO’’), but this effect can also
lead to the activation of human natural killer (NK) cells,
which commit cytotoxic activity against cells downregu-
lated of HLA-I (Lanier, 2008; Vivier et al., 2011; Long
et al., 2013). Therefore, strategies to overexpress single-
chain HLA-E fused with B2M (Gornalusse et al., 2017) or
to disrupt HLA-A/B but retain HLA-C (Xu et al., 2019)
have been proposed. However, allo-PTR due to anti-HLA-
C has been reported (Saito et al., 2002). Furthermore,
whether HLA-KO platelets activate NK cells remains unad-
dressed, including in vivo models with highly reconsti-
tuted human NK cells in circulation. In the present study,
we produced HLA-KO iPLATs by knocking out B2M using
the CRISPR/Cas9 method in our clinically applicable
imMKCL system and evaluated their in vitro functionality
and immunogenicity to NK cells. We also succeeded in es-
tablishing humanized mice with a high reconstitution of
human NK cells by using MSTRG mice injected with
interleukin-15 (IL-15) ligand and IL-15 receptor (Hu-NK-
MSTRG mice) and assessed the circulation of HLA-KO
iPLATs in vivo.
RESULTS
HLA-Null Platelets Were Successfully Produced from a
b2-Microglobulin-Knockout imMKCL
To produce platelets without HLA-I expression, we sought
to create HLA-I-depleted imMKCLs by knocking out the
B2M gene. Because we did not succeed in genome editing
the imMKCLs, we adopted the ‘‘re-reprogramming’’
method (Seo et al., 2018), whereby imMKCLs are first
reprogrammed to iPSCs (MK-iPSCs) and then subjected
to B2M knockout using CRISPR/Cas9 technology
(Figures 1A and 1B). Here, we used already established
imMKCLs, which are highly proliferative and have high
iPLAT production capacity, as the starting material, assur-
ing the derivation of high-quality imMKCLs with the
B2M-KO trait. These B2M-knockout MK-iPSCs bear the
DOX-inducible c-MYC, BCL-XL, and BMI1 transgenes of
the original imMKCLs and were reinduced to imMKCLs
(HLA-KO imMKCLs) and expanded in MK-differentiating
medium including DOX (Figure 1A).
The production of CD41a+CD42b+ iPLATs from HLA-KO
imMKCLs was comparable with the wild-type (WT) coun-
terpart (Figure 1C). HLA-KO iPLATs were confirmed to
lack the surface expression of B2M and HLA-I molecules
(Figures 1D and 1E). The cell-surface characteristics of
HLA-KO iPLATs were comparable with those ofWT iPLATs,
donor platelets provided from the Japanese Red Cross Soci-
ety (JRC), and peripheral blood platelets from healthy do-
nors, as shown by the levels of human platelet antigens
(HPAs) (Figure S1A). The cell size and ultrastructure of
HLA-KO iPLATs were comparable with those of WT iPLATs
(Figures S1B and S1C), which have a similar ultrastructure
to JRC platelets but are slightly larger, as reported
previously (Ito et al., 2018). The in vitro functionality of
HLA-KO iPLATs was also comparable, as shown by the
low level of Annexin V binding and high level of hallmarks
of in vitro platelet activation, namely, PAC-1 binding and
CD62P expression upon stimulation (Figures S1D–S1F).
Finally, HLA-KO iPLATs and WT iPLATs were comparable
for clotting (Figure 1F). These data indicate that the
knockout procedure did not affect the production effi-
ciency or function of iPLATs.
NK Cells Do Not Show Cytotoxic Response against
iPLATs Regardless of HLA-I Expression
To assess whether iPLATs of HLA-KO phenotype preferen-
tially elicit a cytotoxic response by NK cells, we performed
co-culture assays in vitro (Figure 2A). NK cells separated
from the peripheral blood mononuclear cells (PBMCs) of
11 healthy donors (Table 1) were each co-cultured with
iPLATs for 6 h. The response of the NK cells was assessed
by measuring the expression of CD107a, which reflects
the release of cytotoxic granules from NK cells (Alter et al.,
2004). The expression of CD107a was highly enhanced
against K562 cells, a typical positive control leukemic cell
line used for cytotoxic assays, but just baseline level against
WTandHLA-KO iPLATs (Figures 2B andS2A).Wealso tested
the interferon-g (IFN-g) secretion fromNK cells, finding the
response, like CD107a, to be high against K562 cells, but
baseline level against iPLATs (Figure S2B). Furthermore,
Annexin V binding on iPLATswas not observed, suggesting
nocellular damage to iPLATs (Figure S2C). Thus, thedegran-
ulation activity of NK cells was not induced by iPLATs
regardless of HLA-I expression.
iPLATs Do Not Express NK Cell-Activation Molecules
The balance between activation and inhibitory signals reg-
ulates NK cell activity (Lanier, 2008; Vivier et al., 2011;
Long et al., 2013). Therefore, we compared the expression
pattern of ligands for these signals on iPLATs. The major
inhibitory ligands of NK cells, HLA-I molecules, suppress
NK cell activation through killer cell immunoglobulin-
like receptors (KIR). HLA-ABC was expressed on iPLATs
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without B2M knockout as well as on blood donor-derived
platelets from the JRC, but not on B2M-knockout iPLATs,
and had low expression on K562 cells (Figure 1E).
MIC-A, MIC-B, and ULBP family proteins are HLA-I-
related molecules that are induced under stress situations
such as virus infection, and act as activation ligands for
NK cells (Bauer et al., 1999;Wu et al., 1999). The expression
of MIC-A/B and ULBP proteins was not observed in any of
the cells tested, except for ULBP-1 on K562 cells (Figure 3).
Similarly, the DNAM-1 ligands CD112 and CD155 and
NKp30 ligand B7H6, which are other activation ligands
of NK cells (Shibuya et al., 1996; Bottino et al., 2003;
Long et al., 2013; Vivier et al., 2011), were expressed on
K562 cells but not on platelets (Figure 3). Other Nectin fam-
ily proteins, including CD111 (nectin-1), CD113 (nectin-3)
(Martinet and Smyth, 2015), and CD48, a 2B4 ligand (Na-
kajima et al., 1999), were not expressed (Figure S3). Among
the adhesion molecule intercellular adhesion molecule
(ICAM) family proteins, which are ligands for LFA-1 on
NK cells (Barber et al., 2004; Long et al., 2013), ICAM-2
was expressed in all cells, but not differently between plate-
lets and K562 cells (Figure 3).
The major inhibitory ligands are HLA-I, but there are
other inhibitory ligands for NK cells. Cadherin family pro-
teins are inhibitory ligands for KLRG1 receptor on NK cells
(Ito et al., 2006), but E-, N-, and R-cadherin were not
Figure 1. Production of HLA-KO iPLATs
by Knocking Out b2-Microglobulin in
imMKCL
(A) Schema of the HLA-KO platelet produc-
tion procedure. Knockout of b2-micro-
globulin (B2M) by CRISPR/Cas9 failed in
imMKCL. Therefore, imMKCL was first re-re-
programmed to secondary iPSCs (MK-iPSC),
in which B2M was knocked out. MK-iPSCs
were then reinduced to imMKCL (HLA-KO
imMKCL) in the presence of doxycycline
(DOX) and, after expansion, matured to
release iPLATs in DOX-OFF condition.
(B) The targeting strategy of knocking
out B2M by replacing exon 1 to a UBiC
promoter-regulated puromycin-resistant
gene for HLA-I nullification.
(C–E) Flow-cytometry analysis of the
generated CD41a+CD42b+ iPLATs and their
yield (C), and the cell-surface expression of
B2M (D) and of HLA-ABC and HLA-E (E) on
imMKCLs, iPLATs, JRC platelets, and K562
cells. Gray histograms in (D) and (E) repre-
sent no staining control.
(F) Clot retraction assay of iPLATs.
WT, wild type; KO, HLA-KO; JRC, Japanese
Red Cross; N.S., not significant. Data are
representative of three independent exper-
iments with error bars representing the
mean ± SEM. See also Figure S1.
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expressed (Figure S3). Additionally, PD-L1 and PD-L2
modulate NK cell activity through the receptor PD-1
(Benson et al., 2010), and proliferating cell nuclear antigen
(PCNA) and lectin-like transcript-1 (LLT1)modulate NK cell
activity through NKp44 (Rosental et al., 2011) and NKR-
P1A (Rosen et al., 2005), respectively. However, none of
these ligands were expressed on platelets (Figure S3).
Therefore, while K562 cells may activate NK cells through
ULBP-1, DNAM-1 ligands, and B7H6, platelets do not spe-
cifically express ligands that inhibit or activate NK cells.
HLA-KO iPLATs Can Circulate in Humanized Mice
with Abundant Human NK Cells and Anti-HLA-I
Antibodies
Next, we assessed whether HLA-KO iPLATs are rejected by
NK cells in vivo. To generate mice with abundant human
circulating NK cells, we transplanted MSTRG mice that
express human macrophage colony-stimulating factor
(M-CSF), thrombopoietin (TPO), and signal regulatory pro-
tein a (SIRPa) on Rag2/Il2rg/ background (to enhance
human hematopoietic cell engraftment) (Rongvaux et al.,
2014; Saito et al., 2016) with human CD34+ cells derived
from cord blood, then intraperitoneally administered a hu-
man IL-15 and IL-15R-a mixture at 8 and 9 weeks to pro-
mote NK cell reconstitution (Figure 4A). By this method,
MSTRG mice showed a high frequency of human NK cells
in circulation, with the majority being CD56dimCD16+
mature NK cells (hereafter called Hu-NK-MSTRG mice; Fig-
ures 4B, 4C, and S4A). NK cells separated from the spleen of
Hu-NK-MSTRG mice showed CD107a upregulation when
co-culturedwithK562 cells but notwith iPLATs (Figure 4D),
indicating that the NK cells are competent for cytotoxic
function. We further confirmed the in vivo functionality
of human NK cells in the mice by infusing a mixture of
WT and HLA-KO human iPSC-derived hematopoietic
cells. The ratio of HLA-KO was lower in the lungs of
Hu-NK-MSTRG mice than in non-humanized MSTRG
Figure 2. In Vitro Cytotoxic Assay of NK Cells Co-cultured with
iPLATs or imMKCLs
(A) Schema of the in vitro cytotoxic assay in vitro. NK cells and
target cells were co-cultured with 1,000 U/mL human IL-2 for 6 h
and then analyzed.
(B) Flow-cytometry analysis of CD107a expression on NK cells from
11 healthy volunteers co-cultured with K562 cells, WT, or HLA-KO
iPLATs. WT, wild type; KO, HLA-KO. Data are the mean ± SEM of
three independent experiments.
See also Figure S2.
Table 1. HLA Class I Profiles of the imMKCL and NK Cell Donors
(A–K)
HLA-A HLA-B HLA-C C1 C2
imMKCL 02:01 15:01 02:02 +
02:01 15:01 03:03 +
A 02:01 40:01 03:04 +
24:02 15:01 03:03 +
B 02:01 07:02 03:04 +
33:03 40:01 07:02 +
C 24:02 07:02 07:02 +
33:03 58:01 03:02 +
D 11:01 51:01 15:02 +
24:02 40:02 03:04 +
E 33:03 44:03 14:03 +
11:01 15:01 04:01 +
F 02:01 15:01 04:01 +
26:03 44:03 08:01 +
G 24:02 39:01 07:02 +
26:03 35:01 03:03 +
H 24:02 51:01 01:02 +
31:01 35:01 03:03 +
I 24:02 54:01 01:02 +
30:01 56:01 07:02 +
J 11:01 15:01 04:01 +
31:01 56:01 07:02 +
K 24:02 15:01 04:01 +
31:01 35:01 03:03 +
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mice, indicating that the NK cells are competent for cyto-
toxic function against HLA-deficient cells in vivo as well
(Figure S4B).
To assess the circulation capacity of HLA-KO iPLATs, we
transfused a mixture of WT and HLA-KO iPLATs labeled
with TAMRA dye to Hu-NK-MSTRG mice and compared
the ratio between the WT and HLA-KO types in the blood
circulation at various time points (Figure S4C). Circulation
of the transfused iPLATs was observed up to 6 h post trans-
fusion (Figure 4E). Importantly, the ratio of HLA-KO was
stable frompre-injection to up to 6 h (Figure 4F). This result
indicates that HLA-KO iPLATs have the same circulating
capability as WT iPLATs even in the presence of human
NK cells.
In a separate experiment, 20 min prior to the transfu-
sion of iPLATs, mouse anti-HLA-A2 antibody was injected
into Hu-NK-MSTRG mice to create an HLA-I-mediated
allo-PTR model (Gras et al., 2013) (Figure 4G). Similar to
the kinetics in patients with anti-HLA-I antibody-medi-
ated allo-PTR transfused with incompatible donor-derived
platelets, the circulation of HLA-WT iPLATs was less at
30-min transfusion, and only HLA-KO iPLATs were essen-
tially observed after 3 h (Figures 4G, 4H, and S4D). These
data suggest that HLA-KO iPLATs are an effective source
for alloimmune PTR, which is mostly mediated by anti-
HLA-I antibodies.
DISCUSSION
Wehave recently proposed a clinically applicable system to
produce transfusion-relevant numbers of iPLATs from
imMKCLs by using a turbulent flow-based bioreactor and
adding an aryl hydrocarbon receptor antagonist and
Rho-associated protein kinase inhibitor for imMKCLmatu-
ration and iPLAT release (Ito et al., 2018). iPLATs produced
in this system have shown comparable function with
blood donor-derived platelets and are devoid of tumorige-
nicity upon irradiation, a precaution also taken for usual
transfusion products to eliminate the risk of transfusion-
related graft-versus-host disease. Based on this system,
this study shows that HLA-KO iPLATs were successfully
produced from HLA-KO imMKCLs (Figures 1 and S1), and
further found the unique property of HLA-KO iPLATs to
evade NK cell-mediated and anti-HLA-I antibody-mediated
immune responses from in vitro and in vivo assays (Figures
2, 3, 4, and S2–S4). Thus, a functional, safe, and universal
HLA-I iPLAT product can be supplied, resolving the risk
of compatible-donor shortage in HLA-I-mediated allo-
PTR. Because one HLA-KO iPLAT line can be applied for
all HLA-I types, the cost will be significantly lower than
had we prepared autologous iPLATs or a wide line-up of
iPLATs with various HLA-I types from an iPSC library
(Gourraud et al., 2012; Turner et al., 2013).
The nullification of HLA-I on platelets has been achieved
before by knocking out or knocking down B2M to enable
platelets to evade anti-HLA-I alloresponses (Gras et al.,
2013; Feng et al., 2014; Borger et al., 2016). While the
gene knockout procedure is capable of achieving complete
Figure 3. Platelets Do Not Express NK Cell-Activating Molecules
Representative histogram of the flow-cytometry analysis of HLA-I-
related molecules, DNAM-1 ligands, B7H6 (NKp30 ligand), and
ICAM family molecules for iPLATs, JRC platelets, and K562 cells. For
iPLATs, both WT and HLA-KO types were analyzed. Gray histograms
represent isotype control. WT, wild type; KO, HLA-KO. Data are
representative of three independent experiments.
See also Figure S3.
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deletion of theHLA-I expression, itmaynot inhibit the acti-
vation of NK cells through the HLA-I receptor, KIR, thus
leading to rejection of the allografts (Ichise et al., 2017). A
short hairpin RNA (shRNA)-based mRNA knockdown pro-
cedure was reported to leave a low expression level of
HLA-I, which has the potential advantage of suppressing
the NK cell response against HLA-I nullified cells (Wieg-
mann et al., 2014). Other approaches to evade NK
cell response include the overexpression of single-chain
HLA-E fused with B2M (Gornalusse et al., 2017), knockout
of the HLA-A and HLA-B loci while retaining HLA-C (Xu
et al., 2019), and the overexpression of CD47 (Deuse et al.,
2019).However, it has not been addressedwhether platelets
nullifiedwith all HLA-Imolecules elicit anNK cell response,
and thus it remains unknownwhich approach is most suit-
able. In our current study, we found that platelets do not
elicit cytotoxic responses by NK cells even when HLA-I is
completely depleted (Figures 2 and S2). Our data show
that the lack of NK cell-activating receptor ligands such as
DNAM-1 ligands and the NKp30 ligand B7H6 on iPLATs
may be partly involved in this effect (Figures 3 and S3).
We also looked into various ligands and adhesion mole-
cules that could affect NK cell activation, such as non-
DNAM-1 ligand Nectin family molecules, including
Figure 4. HLA-KO iPLATs Successfully
Circulated in a Humanized Mouse Model
with High NK Cell Reconstitution
(A) Schema of the establishment of NK cell-
reconstituted humanized mice (Hu-NK-
MSTRG mice). Four-week-old MSTRG mice
were transplanted with cord blood-derived
human CD34+ cells. At 8 and 9 weeks old, the
mice were intraperitoneally administered
recombinant human IL-15 and IL-15 re-
ceptor a. At 10 weeks old, the mice were
checked for the reconstitution of human
hematopoietic cells and underwent trans-
fusion experiments (n = 8).
(B and C) Representative flow-cytometry
scatterplots of circulating human blood cells
in the mice (B) and the percentage of circu-
lating human CD56+CD3 cells (C) (n = 4).
(D) Human NK cells were purified from Hu-
NK-MSTRG mice and subjected to an in vitro
cytotoxic assay against K562 cells and
iPLATs. CD107a expression on NK cells was
analyzed by flow cytometry (n = 3).
(E and F) The number of total circulating
hCD41a+CD42b+ iPLATs (E) and percentage
of HLA-KO type among circulating iPLATs (F)
in Hu-NK-MSTRGmice at pre-transfusion and
30min, 3 h, and 6 h after transfusion (n = 8).
(G) Schema of the allo-PTR model mice. Hu-
NK-MSTRG mice were injected with mouse
anti-HLA-A2 antibody 20 min prior to the
transfusion of iPLATs.
(H) The percentage of HLA-KO type among
circulating iPLATs in Hu-NK-MSTRG mice
treated with anti-HLA-A2 antibody (allo-
PTR mice) or the isotype control at pre-
transfusion and 30 min, 3 h, and 6 h after
transfusion (n = 3 or 4 in each group).
WT, wild type; KO, HLA-KO. Data are repre-
sentative of three or more independent ex-
periments with error bars representing the
mean ± SEM. *p < 0.05 and **p < 0.01. See
also Figure S4.
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Nectin-1 and Nectin-3, ICAM family proteins, which are li-
gands for LFA-1 on NK cells (Barber et al., 2004; Long et al.,
2013), CD48, which binds 2B4 receptor for activation (Na-
kajima et al., 1999), and cadherins, which bind KLRG1 re-
ceptor to inhibit NK function via ITAM (immunoreceptor
tyrosine-based activation) signaling (Ito et al., 2006; Li
et al., 2009) and also have a functional role in aggregation
and thrombus formation (Dunne et al., 2012). Other inhib-
itory ligands, such as LLT1, PD-L1, PD-L2, and PCNA (Alde-
mir et al., 2005; Rosen et al., 2005; Benson et al., 2010;
Pesce et al., 2017; Rosental et al., 2011), were also analyzed.
However, we did not find a specific lack of activating mol-
ecules or specific expression of inhibitory molecules on the
platelets. We speculate that the inert response may depend
on the non-nuclear properties of platelets, since erythro-
cytes, which are also anucleate and do not express HLA-I,
are not attacked by NK cells, except in specific circum-
stances such as Plasmodium infection (Chen et al., 2014).
Further studies are required, but elucidating how iPLATs
evadeNK cells could contribute to understanding other im-
mune phenomena such as tumor immune evasion.
For in vivo evaluation, we adopted MSTRG mice trans-
planted with human cord blood cells (Figures 4 and S4).
MSTRG mice have an enhanced reconstitution of human
hematopoiesis by knocking in genes encoding human
M-CSF, TPO, andSIRPa into theRag2/Il2rg/background
(Rongvaux et al., 2014; Saito et al., 2016). By further inject-
ing a mixture of human IL-15 ligand and receptor, as previ-
ously reported (Huntingtonet al., 2009),we succeeded in es-
tablishing ‘‘Hu-NK-MSTRG’’mice,which reconstitutedhigh
levels of humanNKcells.Our data showed that the reconsti-
tuted human NK cells in Hu-NK-MSTRG mice have cyto-
toxic activity similar to that ofNK cells in humanperipheral
blood (Figures 4D and S4B). We further set up an allo-PTR
model by injecting mouse anti-HLA antibody. HLA-KO
iPLAT transfusion to this model suggested that HLA-KO
iPLATs could circulate upon transfusion to human subjects,
including allo-PTR patients with anti-HLA-I alloantibodies.
Several groups have previously reported the establishment
of humanized mice with a high reconstitution of NK cells
and have tested the in vivo NK cell functionality (Strowig
et al., 2010; Ku¨bler et al., 2014; Rongvaux et al., 2014; Ka-
tano et al., 2015;Herndler-Brandstetter et al., 2017).Howev-
er, these reports show the in vivo rejection of only tumori-
genic HLA-deficient cells, while this report showed this in
non-tumorHLA-deficient cells, thus providing a pre-clinical
model for HLA-depleted cell therapies. Moreover, there are
no reports on platelet circulation in humanized mice with
a high reconstitution of NK cells and anti-HLA-I antibodies.
There has been a debate about whether platelets capture
circulating B2M to express functional HLA-I (Gouttefan-
geas et al., 2000). With regard to our model, although hu-
man blood cells that express B2M were in circulation, we
did not observe a difference in the ratio of HLA-KO and
WT iPLATs, and their HLA expression level remained un-
changed during the assessment. Based on these observa-
tions, we conclude that iPLATs do not readily upregulate
HLA-I expression through the adoption of circulating B2M.
The production of anti-HPA alloantibodies is the second
major cause of allo-PTR and also a primary cause of fetal/
neonatal alloimmune thrombocytopenia and post-transfu-
sion purpura. However, HPA knockout is not appropriate
due to the existence of antibody-recognition sites on
crucial functional platelet molecules, such as CD61
(ITGB3), CD41 (ITGA2B), CD42b, CD36, and CD29 (Curtis
and McFarland, 2014; Hayashi and Hirayama, 2015). As
such, HPA conversion using the CRISPR/Cas9 system has
been proposed (Zhang et al., 2016). Considering that a sub-
stantial portion of patients with anti-HPA antibodies also
carry anti-HLA-I antibody, HLA-KO iPLATs may be an ideal
platform for further gene editing of HPA.
In conclusion, our study shows a proof of concept that
HLA-KO iPLATs can be used as universal HLA-I-type plate-
lets. This study should lead to the clinical application of
HLA-KO iPLATs for resolving the shortage risk of HLA-I-
compatible donors in allo-PTR conditions and contribute
to the cost reduction of iPLATs. In addition, we also found
that the unique non-immunogenic property of HLA-
depleted platelets does not activate NK cells. Owing to their
capacity to evade alloimmune responses and their safe and
uniform product profile by sterile production from quality-
assured imMKCL master cells, HLA-KO iPLATs may also
lead to new standardized platelet-based therapies such as
injection for tissue regeneration and drug-delivery systems.
EXPERIMENTAL PROCEDURES
Study Approval
Donor-derived human platelets were provided by the JRC. Human
platelets were used in compliance with the Guidelines on the Use
of Donated Blood in R&D from theMinistry of Health, Labour and
Welfare of Japan. The collection and usage of peripheral blood
fromhealthy volunteers, the collection of cord blood fromhealthy
volunteers, and animal experiments were approved by the Ethical
Committee of Kyoto University and Kumamoto University. All ex-
periments using human samples were conducted in accordance
with the Declaration of Helsinki.
Cell Culture
imMKCLs were established from human iPSCs as previously re-
ported (Nakamura et al., 2014). imMKCLs were cultured in
IMDM medium (Sigma) with L-glutamine (25030-081; Thermo
Fisher Scientific), Insulin-transferrin-selenium (41400-045;
Thermo Fisher), 50 mg/mL ascorbic acid (A4544; Sigma-Aldrich),
and 450 mM 1-thioglycerol (M6145; Sigma-Aldrich). DOX-ON
proliferation condition: imMKCLs were cultured with 15%
fetal bovine serum (FBS), 50 ng/mL recombinant human
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thrombopoietin (rhTPO: PeproTech), 50 ng/mL recombinant
human stem cell factor (rhSCF: R&D Systems), and 5 mg/mL
DOX-inducible transgenes (c-MYC, BIM1, and BCL-XL). DOX-
OFF production of iPLATs condition: the medium contained 10%
human plasma (Cosmo Bio #12250210, Japan Blood Products Or-
ganization), 10 U heparin sodium (#(01)14987476163428; Yosh-
ido), 50 ng/mL rhSCF, 200 ng/mL TA-316 (Nissan Chemical),
15 mM KP-457 (Kaken Pharmaceutical), 0.5 mM GNF-351 (Calbio-
chem), and 0.5 mM Y39983 (MedChemExpress). imMKCLs were
cultured with this medium for 6 days in 125- or 250-mL Corning
Erlenmeyer cell-culture flasks (#431143 and #431144; Sigma-Al-
drich) in shaking conditions using Lab-Therm shakers (Kuhner)
(Ito et al., 2018).
MK-iPSCswere established from imMKCLs by re-reprogramming
(Seo et al., 2018) and cultured with themouse C3H10T1/2 cell line
in DMEM F-12 medium (Sigma) with MEM non-essential amino
acids solution (1003) (11140050; Thermo Fisher), penicillin-strep-
tomycin-glutamine (1003) (10378016; Thermo Fisher), 20%
KnockOut Serum Replacement (10828028; Thermo Fisher),
0.1 mM 2-mercaptoethanol (Sigma), and 5 ng/mL basic fibroblast
growth factor (R&D Systems).
K562 cells were cultured with RPMI-1640 medium (Sigma), 10%
FBS, and 1003 penicillin-streptomycin-glutamine (10378016;
Thermo Fisher).
Establishment of a b2-Microglobulin-Knockout
imMKCL
Exon 1 of B2M was selected as the knockout target. The sequence
for homologous recombination was constructed as 50-arms-loxP-
Ubic-Puror-loxP-30-arms. The sequence of the 50-arm was Fw
50-TGG CGG CCG CTC TAG ACC CTT TGT CTT CCA GTG TCT
-30, and Rv 50-ATT ATA CGA AGT TAT GCC CGC ATG CTG TCA
GCT TCA GGA ATG-30; and the 30-arm was Fw 50-ATA CGA AGT
TAT GCA ACA GGG TTT CAC CGT GTT AG-30, and Rv 50-GCT
TGA TAT CGA ATT CGA GGC ACA GTA CAT CTT GGA-30. This
cassette was integrated into pBluescript KS(+) vector using In-
Fusion reaction to construct the targeting vector plasmid. The sin-
gle-guide RNA (sgRNA) expression vector was designed as Guide
Fw 50-TCA TGC CAT CCG TAA GAT GC-30 and Guide Rv 50-CTA
AAA CTA GCT GTG CTC GC-30, and inserted into pHL-H1-ccdB-
mEF1a-RiH vector using In-Fusion reaction to construct the sgRNA
expression vector pHL-H1-B2M-sgRNA-mEF1a-RiH.
MK-iPSC line #11 (MKiPS#11) was established from imMKCLs by
re-reprogramming (Seo et al., 2018). imMKCLs at the DOX-ON
proliferation stage were transfected with an episomal vector car-
rying reprogramming factors (OCT3/4 with shRNA of TP53,
SOX2, KLF4, and MYCL) by using Human Stem Cell Nucleofecto
Kit 2 (VPH-5022; Lonza). The transfected imMKCLs were co-
cultured with the C3H10T1/2 cell line as feeder cells for 3–4 weeks.
iPSC-like colonies were picked up asMK-iPSCs. For genemanipula-
tion, MKiPS#11 was placed into feeder-free culture condition:
iMatrix-511 (892012; MTR)-coated dishes in StemFit AK03N me-
dium (Ajinomoto, Tokyo, Japan). For establishment of B2M-KO
imMKCL, the sgRNA expression vector, the targeting vector, and
the CRISPR/Cas9 expression vector (pHL-UbicP-SphcCas9-iP-A)
were transfected into 0.8 3 106 MK-iPSCs by electroporation.
MK-iPSCs were cultured with 10 mM Y27632 (Wako) for 1 day
and selected with 1 mg/mL puromycin from day 3. Seven days after
the electroporation, individual colonies were picked. After geno-
typing each clone by using PCR primer 1, 50-ACG AAA TGG
CGG CAC CTT AT-30, primer 2, 50-CCC GTC CTA AAA TGT CCT
TC-30, primer 3, 50-CTGCAAGAACTCTTCCTCAC-30, and primer
4, 50-TGG CGC CAT GAT AGC TCA AA-30, an adequately targeted
clone was selected (HLA-KO MK-iPSCs). HLA-KO MK-iPSCs were
placed into the C3H10T1/2 cell co-culture condition. For differen-
tiation to imMKCLs, HLA-KO MK-iPSCs were cultured by the Sac
method (Nakamura et al., 2014). HLA-KOMK-iPSCs were cultured
in differentiationmedium fromday 0 to day 14. After day 14, HLA-
KO hematopoietic progenitor cells were collected from the Sac-like
structure and cultured in imMKCLmediumwith 50 ng/mL rhSCF,
50 ng/mL rhTPO, and 5 mg/mL DOX. The DOX-induced trans-
genes were expressed, and HLA-KO imMKCLs were obtained.
Flow Cytometry
The following antibodies were used: from BD Biosciences,
hCD42b-APC (clone HIP1: 551061), HLA-ABC-FITC (clone G46–
2.6: 557348), b2-microglobulin-FITC (clone TU99; 551338),
hCD3-FITC (clone SP34: 556611), hCD56-PerCP/Cy5.5 (clone
B159: 560842), hCD107a-BV421 (clone H4A3: 562623), and
hCD49b-PE (clone 12F1: 555669); from R&D systems, ULBP-1-PE
(clone 170818; FAB1380P), ULBP-2/5/6-APC (clone 165903;
FAB1298A), ULBP-3-PE (clone 166510; FAB1517P), hOCIL/
CLEC2d(LLT1)-APC (clone 402659; FAB3480A), and B7H6-PE
(clone 875001; FAB7144P); from BioLegend, hCD41a-APC (clone
HIP8; 303710), hCD42b-PE (clone HIP1; 303906), hCD112-PE
(clone TX31; 337409), hCD155-APC (clone SKII.4; 337617),
MIC-A/B-PE (clone 6D4; 320906), HLA-E-PE (clone 3D12;
342603), ICAM-1-Pacific Blue (clone HA58; 353109), ICAM-2-PE
(clone CBR-IC2/2; 328505), ICAM-3-APC (clone CBR-IC3/1;
330011), hCD19-APC/Cy7 (clone HIB19; 302218), hCD45-PE/
Cy7 (clone HI30; 304016), hCD3-FITC (clone UCHT1; 300406),
mCD45.2-PE (clone 104; 109808), hCD56-BV421 (clone HCD56;
318328), hCD16-BV510 (clone 3G8; 560918), hCD324 (E-Cad-
herin)-APC (clone 67A4; 324107), hCD36-APC/Cy7 (clone 5-271;
336213), hCD29-PE (clone TS2/16; 303003), hCD109-PE (clone
W7C5; 323305), hCD61-FITC (clone VI-PL2; 336403), PD-L1-PE
(clone 29E.2A3; 329705), PD-L2-PE (clone 24F.10C12; 329605),
hCD48-PE (clone BJ40; 336707), h/m/rPCNA-PE (clone PC10;
307908), and hCD111-PE (clone R1.302; 340404); from eBio-
science, hCD33-APC (clone WM-53; 17-0338-41) and hCD41a-
efluor 450 (clone HIP8; 48-0419-42); from Santa Cruz Biotech-
nology, N/R-cadherin-Alexa Fluor 647 (clone H-4; sc-271386) and
hCD42c-PE (clone F-11; sc-377129 PE); and from MBL Interna-
tional, hCD113-Alexa Fluor 488 (clone N3.12.4; K0224-A48).
For staining, cells were incubated with antibodies in PBS()
(Sigma) with 3% FBS for 30 min at 4C, except platelets at room
temperature. The data were obtained with a FACS Verse, FACS
Aria IIIu, or FACS Canto II (BD Biosciences), and analyzed by
FlowJo 10.4 (FlowJo).
Clot Retraction Assay
iPLATs were suspended in IMDM medium with 20% human
plasma. iPLATs were then mixed with 2 U/mL thrombin and incu-
bated at 37C for 2 h (Hirata et al., 2017).
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NK Cell Co-culture Assay
PBMCs were isolated from whole blood by density gradient centri-
fugation using Ficoll-Paque PREMIUM (GE Healthcare) from
healthy volunteers. PBMCs were incubated with CD4, CD14, and
CD19 MicroBeads (130-045-101, 130-050-201, 130-050-301; Mil-
tenyi Biotec) at 4C for 30 min. After washing, MACS Columns
(Miltenyi Biotec) were used for the isolation. A mixture of CD4+,
CD14+, and CD19+ cells was used as negative control cells. CD4-
CD14-CD19 cells were incubated with CD3 and CD8 MicroBeads
(130-050-101, 130-045-201; Miltenyi Biotec) at 4C for 30 min,
and cells negatively separated by MACS columns were used
as the NK cell population. For the CD107a expression assay,
13 106 cells/mL humanNK cells were co-cultured with target cells
at an E/T ratio of 1:1 in 200 mL of RPMI-1640 medium with 10%
pooled human serum (inactivated) (12181450; Cosmo
Bio), 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL strepto-
mycin (basalmedium)with 1,000U/mL recombinant human IL-2,
and 1/200 volume of CD107a-BV421 for 6 h at 37C in a 5% CO2
incubator in a 96-well plate. After incubation, the plate was centri-
fuged, and eachwell was resuspended in 100 mL of PBSwith 2%FBS
with anti-CD56-PerCP-Cy5.5 and anti-CD3-FITC antibodies. After
30-min incubation, the samples were analyzed by flow cytometry.
The cytotoxic activities of NK cells were evaluated by measuring
CD107a expression and normalized as follows: relative value of
CD107a = (CD107a positive [%] of NK cells with target cells)/
(CD107a positive [%] of NK cells alone). For Annexin V binding
of the target cells, the E/T ratio was 8:1, 4:1, or 0.25:1 in basal me-
dium with 1,000 U/mL recombinant human IL-2. K562 cells were
labeled by the CellTrace CFSE Cell Proliferation Kit (Thermo Fisher
Scientific). After incubation, the plate was centrifuged, and each
well was resuspended in PBS() with 103 Binding Buffer
(556454; BD Biosciences), Annexin V, and antibodies for hCD41a
and hCD42b. After 30-min incubation, the samples were analyzed
by flow cytometry.
Mouse Model
Human CD34+ cells (1 3 106) were isolated from human cord
blood using the CD34+ Cell Isolation Kit (Miltenyi Biotec) and
intravenously injected into MSTRG (CSF1h/h SIRPAtg THPOh/h
Rag2/ Il2rg/) mice irradiated with 2.5 Gy at 6 weeks old. Four
weeks after the transplantation, the reconstitution of human cells
was confirmed by flow-cytometric analysis. Recombinant human
IL-15 (0.5 mg) (#200-15; PeproTech) and 1.0 mg of recombinant hu-
man IL-15 R alpha Fc chimera protein (#7195-IR-050; RSD) in
200 mL of PBS were intraperitoneally injected at days 0, 3, 7, and
14 at 4 weeks post transplantation. The reconstitution of human
NK cells was confirmed by flow-cytometric analysis. For the allo-
PTR mouse model, 3 mg/body weight (g) of anti-HLA-A2 immuno-
globulin G (#0131HA; One Lambda) in 100 mL of PBS was injected
into Hu-NK-MSTRG mice 20 min before platelet transfusion.
Human NK Cell Isolation from Mouse Spleen
The spleens of mice were minced and filtered through 40-mm cell
strainers to make single-cell suspensions. The suspensions were
treated with ammonium-chloride-potassium lysis buffer to lyse
erythrocytes. CD56-positive NK cells were then isolated using anti-
hCD56 microbeads (#130-050-401; Miltenyi Biotec) and positively
selected through LS columns (#130-122-729; Miltenyi Biotec).
Transfusion Assay
For the platelet analysis, WT and HLA-KO iPLATs were mixed and
labeled with 50-TAMRA (C6121; Thermo Fisher Scientific). iPLATs
(5–83 107 in 100 mL of bicarbonate buffer) were intravenously in-
jected into the mice. Blood samples (10 mL) were collected at
30 min, 3 h, and 6 h after the transfusion.
Statistical Analysis
All data are presented asmeans ± SEMandwere analyzed byGraph-
Pad Prism 5 (GraphPad Software). Statistically significant differ-
ences were determined by one-way ANOVA, Tukey-Kramer test for
multiple comparisons, and two-tailed t test for pairwise compari-
sons. p values are indicated in the figures as *p < 0.05 and **p < 0.01.
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